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receive financial support from industry performed better across our assessment 
criteria. We did not find substantial differences between NMAs published before 
January 1st, 2013, with studies published after that date. ConClusions: There 
is substantial variation in the NMA literature. Consensus among NMA guidelines 
is required to improve methodological quality, consistency, and transparency of 
study conduct and reporting.
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APPlicAtion of DiffeRence-in-DiffeRence MethoDology in 
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objeCtives: Propensity score matching (PSM) and Inverse Probability of Treatment 
Weighting (IPTW) are analytical methods used in comparative effective research 
(CER) to establish comparison groups. However, these methods may not be appli-
cable in studies with small sample sizes and unbalanced comparison groups. 
In such cases, where there is an unbalanced design due to unmeasured factors, 
difference-in-difference (DD) can be applied to estimate treatment effects. This 
research aims to apply DD to a small sample of multiple sclerosis (MS) patients with 
unbalanced comparison groups. Methods: A retrospective study was conducted 
using MarketScan Commercial Claims and Encounters and Medicare Supplemental 
and Coordination of Benefits Databases to compare MS patients who switched from 
glatiramer acetate (GA) to fingolimod (FTY) with another group maintaining con-
tinuous use of GA. IPTW and DD were applied to balance the comparison groups; 
PSM could not be implemented due to imbalance between groups. Using DD, the 
treatment effect (i.e. % of patients with relapse) was measured in the 1-year baseline 
period and the 1-year follow-up period as: (difference in relapses in the GA--> FTY 
group) minus (difference in relapses in the GA-only group). Results: IPTW was first 
employed to balance the two groups (GA--> FTY [n= 363]; GA-only [6,416]). Despite 
implementation of IPTW, the comparison groups could not be balanced on multiple 
factors such as patient demographics and clinical characteristics; therefore, DD was 
utilized. In the DD analysis, the % of patients with relapse in the GA--> FTY group 
in the baseline and follow-up periods were 30% and 13.8%, respectively (D= 16.2%); 
in the GA-only group, the % of patients with relapse in the baseline and follow-up 
periods were 14% and 11.5%, respectively (D= 2.5%). The estimated reduction of MS 
relapse rate from FTY was 13.7% (DD= 16.2%-2.5%). ConClusions: DD is an effec-
tive methodology which allows for estimating treatment effects from populations 
with unbalanced comparison groups.
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objeCtives: It is estimated that up to 400,000 persons in Mexico are hospital-
ized yearly for deep-vein thrombosis (DVT). DVT is the presence of a blood clot 
(thrombus) in the deep veins of the body. The main objective was to indirectly 
compare the use of tinzaparin, nadroparin and enoxaparin in terms of safety and 
efficacy for the treatment of deep-vein thrombosis using a network meta-analysis 
(NMA). Methods: To identify suitable studies for a systematic review of treat-
ment of DVT (submitted for abstract), the following databases were searched: 
MEDLINE, Pubmed, EMBASE, CENTRAL (all via The Cochrane Library), Imbiomed, 
HTA, for relevant studies recorded between April 1994 to April 2014. Only ran-
domised controlled trials assessing patients with DVT were included. Studies 
had to report the proportion of patients having recurrence of DVT (efficacy) and 
the proportion of patients having major bleeding (safety). Titles and abstracts 
were screened, data were extracted and risk of bias assessment was undertaken. 
. Bayesian NMA was used to compare the different interventions. Results: Four 
studies, assessing four low molecular weight heparins (LMWH), were judged to be 
sufficiently comparable for inclusion in the NMA. For the proportion of patients 
having recurrence of DVT or major bleeding, enoxaparin 1 mg/kg twice daily, tin-
zaparin 175 IU/kg once daily and nadroparin 100 IU/kg twice daily had a higher 
probability of being more effective and safe than unfractioned heparin. None of 
the LMWHs demonstrated a signiﬁcant superiority over each other in terms of 
efficacy and safety; therefore, the group of LMWHs is suitable for a further cost 
minimization analysis and reference price implementation. ConClusions: We 
found no evidence of differences between tinzaparin, nadroparin and enoxaparin 
for recurrence of DVT and major bleeding. Tinzaparin may be preferred by clini-
cians because it is always given once daily.
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objeCtives: The use of indirect comparisons (IC) is now an integral part of the 
Health Technology Assessment (HTA). When new interventions are assessed, 
Individual patient data (IPD), if available, can be used for comparison with pub-
lished aggregated (AGR) data. Methods exist to assess heterogeneity and incon-
sistency of IC; however in the absence of sufficient studies, IC may be required 
where differences may exist between inclusion/exclusion criteria, definition of 
outcomes and patient characteristics. Signorovitch (2010) has proposed the use 
of MAIC when IPD is available and provided various methods for matching the 
IPD to the AGR study. Methods: Through simulations we assessed different 
approaches to weight calculations, including weighting as originally proposed 
translated into 17 Asiatic languages (Chinese for China, Hong Kong, Singapore 
and Taiwan, Korean, Bengali, Gujarati, Hindi, Kannada, Malayalam, Marathi, 
Punjabi, Telugu, Urdu, Tamil for India and Singapore, and Malay for Singapore). 
The objective of this study was to identify the main translation challenges, and 
which items needed the most references to conceptual definitions. Methods: In 
each country, the linguistic validation was conducted with the author of the IBS-
QOL, using either the standard forward/backward methodology or the adjusted 
process with reviews by the author, a clinician, and cognitive interviews with 12 
patients. The basis for discussion was the list of concepts (LOC) elaborated with 
the author. For each country, the history grid of the translation process was ana-
lyzed. References/reminders of the LOC and author’s interventions were counted for 
each item across countries. Results: Eleven items were found challenging (items 
2,3,4,7,9,16,18,25,28,31,32). Four of them needed the most to refer to the LOC, i.e., 
item 3 “I am bothered by how much time I spend on the toilet” (100% of the coun-
tries); item 18 “I feel I get less done…” (53%); item 25 “I feel sluggish…” (76%); and 
item 31 “I worry about losing control of my bowels” (59%). For instance, the main 
difficulties with item 3 were conceptual (“on the toilet” not to be confused with “in 
the toilet”), and cultural (e.g., lack of toilets in India, or people squatting, not sitting). 
Examples of challenges will be provided. ConClusions: The development of the 
LOC with the author proved to be critical to the translation process and enabled the 
conceptual harmonization of the translations.
ReseARch on MethoDs – statistical Methods
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objeCtives: Matching-adjusted indirect comparison (MAIC) has been proposed as 
a new tool when conducting indirect treatment comparisons in the situation where 
individual-level data are available from one study, but only summary data are avail-
able from another study. This study evaluated the performance of the MAIC method 
proposed by Malangone and Sherman (2011) which is implemented by a resampling 
(bootstrapping) technique. Methods: Two patient-level data sets, similar to two 
clinical trials, were generated: the first with treatments A and placebo, and the 
second with treatments B and placebo. Other variables included in both data sets 
were survival time, censoring indicator, and two baseline categorical variables. In 
both data sets, interactions between baseline characteristics and treatments were 
incorporated such that differential treatment effects across baseline strata were 
present. The SAS programs illustrated in Malangone and Sherman were adopted for 
the MAIC analysis. First, MAIC was applied to a situation in which only summary 
data were available from the first data set and individual-level data were available 
from the second data set. Subsequently, the roles of two data sets were switched 
and the MAIC analysis was applied once again. Results: Using MAIC, when the 
first data set provided summary statistics, the hazard ratio (HR) (95% confidence 
interval [CI]) for A versus placebo was 0.283 (0.246-0.325); the HR (95% CI) for B ver-
sus placebo was 0.586 (0.466, 0.740). When the second data set provided summary 
data, the HR (95% CI) for A versus placebo was 0.489 (0.390-0.612) and for B versus 
placebo was 0.237 (0.205-0.273). The two comparisons produced opposite significant 
inferences. ConClusions: The method proposed by Malangone and Sherman is 
an interesting addition to the MAIC field, but results could be misleading under 
some circumstances. Therefore, the conditions under which this method is suitable 
should be explored further.
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objeCtives: To evaluate the methodological quality of published network meta-
analyses (NMA). Methods: We performed a systematic review of the NMA lit-
erature (through July 2014). For NMAs including pharmaceuticals we assessed 
general study characteristics, study reproducibility and transparency, methods, 
and reporting of findings. We compared NMAs published in higher impact factor 
journals with those published in lower impact factor journals, NMAs published 
before January 1st, 2013, with those published after that date, and studies receiv-
ing financial support from industry with those receiving financial support from 
non-profit institutions or that did not receive support. Results: The systematic 
literature search identified 318 NMAs meeting our inclusion criteria. Forty-eight 
percent of NMAs were published after January 1st 2013, and the majority received 
financial support from non-profit institutions or did not receive support (68%). 
We found notable inconsistencies among NMAs. Eighty percent reported search 
terms, 65% presented sufficient data to reproduce the analysis, 90% the study 
characteristics of included clinical trials, and 61% the network diagram. Seventy 
percent reported a risk of bias assessment of included clinical trials, 56% a sensi-
tivity analysis, and 40% an assessment of model fit. Among NMAs with a closed 
loop, 69% assessed the consistency of direct and indirect evidence. Sixty-four 
percent of NMAs presented the complete matrix of head-to-head treatment com-
parisons. For Bayesian NMAs, 41% reported the probability of each treatment being 
best, 31% reported efficacy ranking, and 16% reported or referenced the model 
code. NMAs published in higher impact factors journals and those that did not 
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objeCtives: Network meta-analysis (NMA) is increasingly used to inform reim-
bursement decisions and comparative effectiveness. Nevertheless, there is limited 
understanding of the assessment of statistical power, particularly when there is a 
small number of studies available. We propose an empirical calculation for statistical 
power using a simulation approach. Methods: Simulation data were generated in 
minimum of 3 to maximum of 15 studies per network, using varying effect sizes and 
standard errors under the exchangeability assumption; where trial-specific treat-
ment effects (δ ij) came from a common distribution with mean (dij ) and variance 
(σ 2). The common distribution is usually chosen to be a normal distribution, so that 
δ ij˜N(dij, σ 2) where i,j are different treatments. Upon generation of simulation data, 
Bayesian methods were applied to each simulation set. This was repeated at least 
1000 times, which enabled the estimation of the statistical power. We compared 
the results of simulations to the gold standard, defined by available data from each 
study, and Thorlund’s method. Results: The proposed method was successful in 
estimating the statistical power and the minimum number of studies needed, using 
simulation data from an NMA, compared to the gold standard. The estimations 
for statistical power/number of studies needed by different effect sizes, standard 
errors, and noise levels were compared with Thorlund’s method showing more 
accuracy to estimate statistical power for NMA. Our method offers flexibility and 
can be implemented with Normal, Binomial, and Poisson distributions. Further, it 
can also handle multiple treatments, fixed/random effects models, and multi-arms 
studies. ConClusions: While it is difficult to derive a mathematical formula for 
estimating statistical power and the number of studies needed in NMA because 
of increased complexity caused by multiple treatment comparisons, an empirical 
method using simulations allows for estimation of these quantities. The proposed 
method will be useful for researchers designing NMA to inform decision makers.
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objeCtives: to measure the DM social cost based in earnings losses of Brazilian 
workers due to disease in 2008 using data from National Survey of Households 
(PNAD/IBGE). Diabetes Mellitus (DM) is characterized by the high level of blood glu-
cose. Ministry of Health data estimated that Brazil had about 10 million DM cases in 
2010, being the fourth main cause of death. WHO estimated the prevalence of DM in 
Brazil is 10.2%, about 20 million people. Methods: a Binary Probit model to meas-
ure the participation in work force and a two-stage Heckman model to measure 
worked hours and productivity. Each model is estimated separately for both gender 
individuals, with and without disease, according three distinct definitions for DM: 
Restrict, Broad and Comorbidities. To capture the counterfactual effect, the model 
was calculated for ill and healthy individuals. The difference of both values exhib-
ited the losses, which were aggregate to the whole population and the total cost 
was estimated. Results: According each criterion, respectively, DM reduced the 
participation in the labor market in 0,97%; 4,60% and 7,06% for men and 0,14%; 4,79% 
and 6,44% for women, while reduced, respectively 1,51%; 6,40% and 9,15% in produc-
tivity and 6,44%; 15,23% and 17,58% in worked hours just for women. There was no 
impact of DM on productivity and in worked hours for men. The DM total cost was 
R$ 8,064 billion, or US$ 3,451 billion converted by current exchange rate. The losses 
reached 0,73% of total earnings and 0,27% of Brazilian GDP in 2008. ConClusions: 
DM generates significant losses in income of Brazilian workers, especially in relation 
to their participation in the labor market, since affects both of gender. The results 
indicate that public policies should be directed to disease diagnosis and prevention, 
since the development of comorbidities amplifies the effect of losses.
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objeCtives: Cluster analysis (CA) is a widely used statistical technique that helps 
reveal classifications of entities with similar characteristics in large data sets. 
However, little is known about whether it can be applied to healthcare claims data 
with highly skewed cost information. This study applied different clustering meth-
ods to changes in all-cause cost data from a group of patients with end stage renal 
disease (ESRD) who initiated hemodialysis (HD). Methods: A retrospective, cross-
sectional, observational study was conducted using the MarketScan Commercial 
Claims database. Patients aged ≥18 years with ≥2 ESRD diagnoses who initiated HD 
between 2008 and 2010 were included. The K-means CA method and hierarchical 
CA with various linkage methods were applied to all-cause costs within baseline 
(12-month pre-HD) and follow-up periods (12-month post-HD) to identify clusters. 
Demographic, clinical, and cost information were extracted from both periods, 
and then examined by cluster. Results: A total of 18,380 patients were identified. 
Meaningful all-cause cost clusters were generated using K-means and hierarchical 
CA with either flexible beta or Ward’s methods. Based on cluster sample sizes and 
change of cost patterns, the K-means CA method and 4 clusters were selected: 
those with average costs in both periods (n=16,624); high costs followed by very 
high costs (n=113); high and increasing costs (n=1,554); or very high costs reduced 
to high cost (n=89). Relatively stable costs after starting HD were associated with 
more stable scores on comorbidity index scores from the pre- and post-HD periods, 
while increasing costs were associated with more sharply increasing comorbidity 
by Signorovitch (WS) vs. Entropy Balancing (EB). WS is based on propensity 
score weights (odds of being in AGR trial) while EB relies on a maximum entropy 
reweighting scheme. Results: Simulation show the optimal weighting method 
is to match on covariates against the AGR treatment and control arms separately. 
In addition, rebalancing on prognostic variables between the IPD arms using EB 
is beneficial when they are not reported in AGR. For example, with true treat-
ment mean difference between AGR and IPD (IC) of one, six predictive variables 
in AGR and IPD and three prognostic variables in IPD, the Bucher method gives a 
biased estimate 0.31(Average Bootstrap 95% Confidence interval: -0.45, 1.08). WS 
balancing gives 0.99(0.23 –1.73), balancing on each arm separately gives 0.99(0.30-
1.68) while rebalancing using EB gives 0.99(0.47-1.52). Also, simulations demon-
strate that including placebo response into the weighting in addition to baseline 
covariates can produce biased results and is not recommended. ConClusions: 
MAIC can be improved if weighting is performed on each arm separately 
together with rebalancing of the IPD on the prognostic variables not reported 
in AGR.
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objeCtives: In 2012, the FDA issued Drug Safety Communications on several 
drugs associated with QT prolongation and fatal ventricular arrhythmias. Among 
these was citalopram, a selective serotonin reuptake inhibitor (SSRI) commonly 
used to treat posttraumatic stress disorder (PTSD). As minimal research has 
assessed drug-related QT prolongation in patients with severe mental illnesses, 
this study explores psychotropic drugs associated with QT prolongation among 
Veterans diagnosed with PTSD. Methods: Patients with PTSD in the Veterans 
Health Administration in 2006-2009 were reviewed, identifying 176 Veterans diag-
nosed with QT prolongation. Cases were matched 1:4 on age, gender, visit date and 
setting, and physical comorbidity. Classification trees assessed QT prolongation 
risk among prescribed medications for the combined sample (N= 880). Finally, 
five-year survival by prolonged QT status was analyzed. Results: Receipt of any 
drug with known risk of QT prolongation varied by group (23% QT vs. 15% con-
trol, p< 0.01). Psychotropic medications conferring significant risks included the 
antipsychotic ziprasidone (3% vs. 1%, p= 0.02) and the anxiolytic buspirone (6% 
vs. 2%, p= 0.01) but not the SSRIs citalopram and fluoxetine. Classification trees 
found sotalol and the tricyclic antidepressant amitriptyline carried greater risk 
among cardiac patients, and methadone, especially if prescribed with quetiapine, 
among non-cardiac patients. Per preliminary adjusted survival model, patients 
with QT prolongation were at increased risk for mortality (HR= 1.60; 95% CI: 1.04-
2.44). ConClusions: Decision models are particularly advantageous when 
exploring nonlinear relationships or non-additive interactions. These findings 
may potentially impact clinical decision-making concerning treatment for PTSD. 
For patients at higher risk of QT prolongation, antidepressants other than ami-
triptyline should be considered. Medications for comorbid conditions should also 
be closely monitored for heightened risk of QT prolongation. This study further 
highlights the importance of routine use of electrocardiograms for QT monitoring 
among patients with PTSD taking these agents.
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objeCtives: Methods of analyzing real world evidence (RWE) have tradition-
ally focused on population-based outcome assessments, whereas the applica-
tion of RWE to address healthcare decision making for the individual patient 
is less well established. The primary objective of this study was to systemati-
cally review published methods using real world data sources to inform patient-
level and patient-provider decision making. Methods: A systematic literature 
review was conducted in MEDLINE and PsychInfo from 1/1/2000 to 9/18/2014. The 
search strategy included methodology, design and limited publications to can-
cer, diabetes, cardiovascular, Alzheimer’s disease, and rheumatologic conditions. 
A review of reference lists of identified articles enhanced the search strategy. 
Eligible studies were quantitative research that described statistical method-
ologies applicable to patient-provider decision making. Non-English and non-
human studies were excluded. Articles were also excluded if they were qualitative 
research studies, reviews, policy/guidelines statements, or studies solely inves-
tigating a provider’s perspective. Following dual eligibility review, details of the 
study and research methodology were extracted and summarized. Results: The 
search strategy identified 1088 publications. A preliminary review of 594 articles 
found 46 that were eligible. The methodologies used included prediction models 
based on logistic, multiple regression and Cox-regression models, multivariate 
risk analyses, discrete choice experiments, net reclassification, and classifica-
tion trees. The review is currently ongoing and additional eligible articles will 
be identified. Details of the application of these methods to patient-provider 
decision making will be presented at the meeting. ConClusions: There is a 
need to incorporate methods in research studies to support evidence-based 
patient-level decision making. This systematic literature review has sought to 
identify methods and exemplars that will enable researchers to produce work to 
inform patient-provider decision making. This review will make recommenda-
tions regarding appropriate methods for scientists and investigators conducting 
patient-centered research. Future research should consider these approaches 
to incorporate methods that will support evidence-based patient decision 
making.
